Neoantigen vaccine clinical trials
Ended Awarded Last action
- Contract number
- 75N91020F00018
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,667,590
Award facts
- Opportunity
-
- NCIDCTD200110 Solicitation number
- Contract value 64% obligated
-
- $4,667,590.00 Current, with exercised options
- $7,268,416.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | -$1,126,751 | |
| Terminate for Convenience | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $5,794,341 |
About this award
The National Cancer Institute awarded Leidos Biomedical Research Inc. a delivery order contract valued at $7.27 million for neoantigen vaccine clinical trials, with performance in Frederick, Maryland and an ultimate completion date of September 24, 2025. This cost-plus-fixed-fee contract implements the President's Department of Government Efficiency cost efficiency initiative and does not utilize a set-aside designation. Leidos Biomedical Research, a subsidiary of Leidos Holdings Inc. and Federally Funded Research and Development Center contractor, brings extensive biomedical research capabilities and experience conducting clinical trials across multiple therapeutic domains, including vaccine development and cancer research.
The contract engages two primary subcontractors to support the vaccine clinical trials program. Mitchell Group Inc., a minority-owned, veteran-owned small business based in Washington, D.C., provides operational and administrative support for clinical research site operations, including human resources management, financial management, supply chain procurement, logistics, facilities management, and community engagement through the UCRC PREVAC program. Incadence Strategic Solutions LLC supplies biometric technology platform services for clinical research studies in West Africa, managing fingerprint and identification systems to streamline participant enrollment, consent, and follow-up processes that support more efficient clinical trial execution and data collection.
Quick answers
Who was awarded contract 75N91020F00018?
75N91020F00018 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 25, 2020.
How much is contract 75N91020F00018 worth?
The government has obligated $4,667,590 on 75N91020F00018. Its potential value, with all options, is $7,268,416.
Is contract 75N91020F00018 an order under another contract?
Yes. 75N91020F00018 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91020F00018 competed?
The extent of competition for 75N91020F00018 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award